

GSK's Synflorix: closer to a different marketplace?

LONDON, UK----28th January 2009----ExpertREACT. Recently the EU Committee For Medicinal Products for Human Use (CHMP) adopted a positive opinion to recommend a marketing authorisation for GSK's new *pneumococcal* vaccine, Synflorix. The vaccine will compete in a fiercely competitive market dominated by Wyeth (PCV-7). With the recent Pfizer news, GSK are no doubt hoping the acquisition may affect an optimum PCV-13 launch. They also have longer-terms plans for *pneumococcal* vaccines

*****NOTE***** This article is available for **ExpertREACT** subscribers only.
Please visit www.vacZine-analytics/products-expertreact

References:





- 1) Committee for Medicinal Products for Human Use. Summary of Positive Opinion for Synflorix. London, 22 January 2009. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Synflorix_1312009en.pdf. Accessed: January 2009
- 2) GSK Corporate Press Release, 11th June 2008. Available at: http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10062.htm. Accessed: January 2009
- 3) Crucell Corporate Press Release. Crucell and Wyeth in discussion on a combination of the two companies. January 7th 2009. Available at: http://cws.huginonline.com/C/132631/PR/200901/1280875_5_5.html. Accessed: January 2009.
- 4) Prymula R., et al. *Pneumococcal* capsular polysaccharides conjugated to protein D for the prevention of acute otitis media caused by *Streptococcus pneumoniae* and non-typable *Haemophilus influenzae*: a randomized double-blind efficacy study. *Lancet* 2006; 367:740-748.
- 5) Centers for Disease Control and Prevention (CDC). Prevention of *pneumococcal* disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 1997; 46 (RR-8): 1-24
- 6) Snedecor., SJ et al. Significant Disease Burden Predicted to Remain in Elderly US adults 6 years After Introduction of 7-valent *Pneumococcal* Conjugate Vaccine (PCV7) in Young Children. Poster 2077. Presented at the 48th Annual ICAAC/IDSA meeting. Washington DC, October 25-28, 2008.
- 7) Vaccine Pipeline Review (CAT No: VAVS014), October 2008. Published by **VacZine Analytics**

A **printable** version of this article can be requested at info@vacZine-analytics.com. For more information about VacZine Analytics products and services please visit www.vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is a new strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new

© 2009 VacZine Analytics. All rights reserved.



ExpertREACT™ service

January 28th, 2009

© 2009 VacZine Analytics. All rights reserved.

